clinical trials

News

Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

News

Shares in BridgeBio rose after it revealed data from a trial of infigratinib in achondroplasia, raising the prospect of the first oral treatment.

News

Chasing Novo Nordisk and Eli Lilly, Kailera and Hengrui have reported 12.1% weight loss in phase 2 with their oral GIP/GLP-1 agonist ribupatide.

Patients

Is patient-centred trial design becoming a strategic advantage for mid-size pharma, helping cut risk, improve timelines, and engage patients?

News

Roche looks on track to add oral BTK inhibitor fenebrutinib to treatment options for primary progressive multiple sclerosis.

News

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.